As of close of business last night, Karyopharm Therapeutics Inc’s stock clocked out at $1.51, up 12.69% from its previous closing price of $1.34. In other words, the price has increased by $+0.1700 from its previous closing price. On the day, 1724820 shares were traded.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Ratios:
To gain a deeper understanding of KPTI’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 3.32 and its Current Ratio is at 3.37.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Piper Sandler on January 19, 2023, initiated with a Overweight rating and assigned the stock a target price of $8.
On November 04, 2022, RBC Capital Mkts Upgraded its rating to Outperform which previously was Sector Perform and also upped its target price recommendation from $7 to $10.
JP Morgan Upgraded its Underweight to Neutral on February 09, 2022, while the target price for the stock was maintained at $8.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Mar 05 ’24 when Paulson Richard A. sold 3,573 shares for $1.30 per share. The transaction valued at 4,645 led to the insider holds 1,160,836 shares of the business.
Paulson Richard A. sold 19,374 shares of KPTI for $23,249 on Mar 01 ’24. The President and CEO now owns 1,164,409 shares after completing the transaction at $1.20 per share. On Mar 01 ’24, another insider, Mason Michael, who serves as the EVP, CFO & Treasurer of the company, sold 6,162 shares for $1.20 each. As a result, the insider received 7,394 and left with 398,756 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, KPTI now has a Market Capitalization of 172.60M and an Enterprise Value of 158.17M. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.19. Its current Enterprise Value per Revenue stands at 1.08 whereas that against EBITDA is -1.34.
Stock Price History:
Over the past 52 weeks, KPTI has reached a high of $4.87, while it has fallen to a 52-week low of $0.62. The 50-Day Moving Average of the stock is 1.1345, while the 200-Day Moving Average is calculated to be 1.2775.
Shares Statistics:
It appears that KPTI traded 1.89M shares on average per day over the past three months and 1.46M shares per day over the past ten days. A total of 114.92M shares are outstanding, with a floating share count of 105.69M. Insiders hold about 8.15% of the company’s shares, while institutions hold 66.39% stake in the company. Shares short for KPTI as of Feb 29, 2024 were 23.44M with a Short Ratio of 12.37, compared to 18.9M on Jan 31, 2024. Therefore, it implies a Short% of Shares Outstanding of 20.37% and a Short% of Float of 20.72%.
Earnings Estimates
As of right now, 7 analysts gave their recommendation on the stock of the company. On average, analysts expect EPS of -$0.33 for the current quarter, with a high estimate of -$0.28 and a low estimate of -$0.37, while EPS last year was -$0.3. The consensus estimate for the next quarter is -$0.31, with high estimates of -$0.27 and low estimates of -$0.34.
Analysts are recommending an EPS of between -$1.09 and -$1.33 for the fiscal current year, implying an average EPS of -$1.23. EPS for the following year is -$1.01, with 7 analysts recommending between -$0.77 and -$1.27.
Revenue Estimates
In the current quarter, 6 analysts expect revenue to total $34.47M. It ranges from a high estimate of $38.36M to a low estimate of $31.7M. As of the current estimate, Karyopharm Therapeutics Inc’s year-ago sales were $36.6M, an estimated decrease of -5.80% from the year-ago figure. For the next quarter, 6 analysts are estimating revenue of $36.42M, a decrease of -3.10% over than the figure of -$5.80% in the same quarter last year. There is a high estimate of $39.4M for the next quarter, whereas the lowest estimate is $34.6M.
A total of 6 analysts have provided revenue estimates for KPTI’s current fiscal year. The highest revenue estimate was $150.84M, while the lowest revenue estimate was $142.44M, resulting in an average revenue estimate of $146.52M. In the same quarter a year ago, actual revenue was $146.03M, up 0.30% from the average estimate. Based on 6 analysts’ estimates, the company’s revenue will be $164.74M in the next fiscal year. The high estimate is $209.72M and the low estimate is $130.2M. The average revenue growth estimate for next year is up 12.40% from the average revenue estimate for this year.
